AVIR Atea Pharmaceuticals
- 3.905
- +0.075+1.96%
Atea Pharmaceuticals News
Atea Pharmaceuticals | DEFA14A: Others
Atea Pharmaceuticals | DEF 14A: Definitive information statements
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Atea Pharmaceuticals | 8-K: Current report
Atea Pharmaceuticals | DEFA14A: Others
Atea Pharmaceuticals | DEFA14A: Others
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Atea Pharmaceuticals | DEFA14A: Others
Atea Pharmaceuticals | DEF 14A: Definitive proxy statements
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Atea Pharmaceuticals | 8-K: Current report
Atea Pharmaceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Atea Pharmaceuticals | 8-K: Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Atea Pharmaceuticals | DEFA14A: Others
Atea Pharmaceuticals | DEF 14A: Definitive proxy statements
Atea Pharmaceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Analysis
Price Target
No Data
